| content | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
Bimatoprost
|
|
| Systematic (IUPAC) name | |
| 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)- cyclopentyl]-N-ethyl-hept-5-enamide | |
| Identifiers | |
| CAS number | |
| ATC code | S01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C25H37NO4 |
| Mol. mass | 415.566 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Topical (eye drops) |
Bimatoprost (sold in the U.S. and Canada by Allergan, under the trade name Lumigan) is a prostamide used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension. It reduces intraocular pressure (IOP) by increasing the outflow of aqueous fluid from the eyes.[1] It has also been used and prescribed off-label to lengthen eyelashes.[2]
Contents |
Cosmetic use
In patients using ophthalmic prostaglandins such as travoprost and latanoprost, as well as prostamides like bimatoprost, it has been anecdotally noted that they have grown long and lush eyelashes. Allergan has initiated clinical trials investigating the usage of Lumigan as a cosmetic drug.[3]
Several cosmetics companies have released products based on a prostaglandin analogs, as non-drug cosmetics.
- Age Intervention Eyelash and Age Intervention Eyelash by Jan Marini Skin Research
- RevitaLash by Athena Cosmetics Corp.
- MD Lash Factor by PhotoMedex Inc.
These companies have been sued by Allergan for patent infringment.[3] The FDA has seized Age Intervention Eyelash as an "unapproved and misbranded drug" because Jan Marini Skin Research promoted it as something that increases eyelash growth[4] and because it is "adulterated" with bimatoprost.[5]
Formulations
Lumigan is a 0.03% solution of bimatoprost, and contains benzalkonium chloride as a preservative. Contact lenses should therefore be removed before use, and replaced no less than 15 minutes later;[1] other eye drops or ointments should be given no less than 5 minutes before or after bimatoprost.[1] It is administered once daily.
Side effects
Possible side effects of this medication are:
- May cause optic nerve damage
- May cause blurred vision;
- May cause eyelid redness;
- May permanently darken eyelashes;
- May cause eye discomfort;
- May eventually cause permanent darkening of the iris to brown (heterochromia).
- May cause a temporary burning sensation during use.
- May cause thickening of the eyelashes.
- May cause severe depression with suicidal ideation
On November 19, 2007 the FDA issued a warning during the seizure of a bimatoprost-containing cosmetic.[6]. The warning stated that "the extra dose of bimatoprost may decrease the prescription drug's effectiveness. Damage to the optic nerve may lead to decreased vision and possibly blindness."
References
- ^ a b c "Bimatoprost Ophthalmic". MedlinePlus (January 1, 2003). Retrieved on 2007-11-19.
- ^ "Drug That Lengthens Eyelashes Sets Off Flutter", The Wall Street Journal (2007-11-19). Retrieved on 2007-11-19.
- ^ a b Wall Street Journal: Drug That Lengthens Eyelashes Sets Off Flutter RHONDA L. RUNDLE November 19, 2007; Page B1
- ^ MSNBC: FDA Seizes $2 Million Of Potentially Harmful SJ Eye Product KNTV-TV 2:44 p.m. ET, Sat., Nov. 17, 2007
- ^ Reuters: U.S. seizes discontinued eyelash product Jim Wolf Fri Nov 16, 2007 11:48pm EST
- ^ U.S. Food and Drug Administration (November 19, 2007). "Potentially Harmful "Cosmetic" Eye Product Seized". Press release. Retrieved on 2007-12-05.
Citations
- Chen M, Cheng C, Chen Y, Chou C, Hsu W (2006). "Effects of bimatoprost 0.03% on ocular hemodynamics in normal tension glaucoma.". J Ocul Pharmacol Ther 22 (3): 188–93. doi:. PMID 16808680.
- Kruse P, Rieck P, Sherif Z, Liekfeld A (2006). "Cystoid macular edema in a pseudophakic patient after several glaucoma procedures. Is local therapy with bimatoprost the reason?". Klin Monatsbl Augenheilkd 223 (6): 534–7. doi:. PMID 16804825.
- Steinhäuser S (2006). "Decreased high-density lipoprotein serum levels associated with topical bimatoprost therapy.". Optometry 77 (4): 177–9. PMID 16567279.
External links
- Medical News Today: FDA Seizes $2 Million Of Cosmetic Eye Product Which Contains Drug Ingredient And Makes Unapproved Drug Claims Christian Nordqvist 18 Nov 2007 - 11:00 PST
- Wired Science: FDA Seizes Cosmetic That Can Blind Brandon Keim November 19, 2007 11:00:00 AM
|
||||||||||||||||||||
|
||||||||
